Fig. 1.

Persistence with denosumab at 12 months. a Primary analysis: percentage of patients who received a second injection of denosumab within 6 months + 8 weeks. b Sensitivity analyses: percentage of patients who received a second injection of denosumab within 6 months + 4, 6, or 12 weeks. The dashed lines in b represent the proportion of patients who were persistent at the primary endpoint time window of 6 months + 8 weeks. N number of patients in the overall cohort and in each country. n number of patients who were persistent in each group. CI confidence interval, US United States